Frontiers in Oncology最新文献

{"title":"Comparative assessment of the diagnostic efficacy of [18F]AlF-NOTA-FAPI-04 and [18F]FDG PET/CT imaging for detecting postoperative recurrence in gastric cancer patients: a pilot study","authors":"Jian Yang, Yong Wu, Yanyin Zhang, Xiang Peng, Chengzhi Jiang, Wanjing Zhou, Jiashun Dai, Aimin Xie, Hui Ye, Kai Zheng","doi":"10.3389/fonc.2024.1427649","DOIUrl":"https://doi.org/10.3389/fonc.2024.1427649","url":null,"abstract":"PurposeThis study aimed to compare the efficacy of [<jats:sup>18</jats:sup>F]AlF-NOTA-FAPI-04 PET/CT with that of [<jats:sup>18</jats:sup>F]FDG PET/CT for detecting postoperative recurrence in patients with gastric cancer.MethodsThis single-center retrospective clinical study was performed at Hunan Cancer Hospital between December 2020 and June 2022. The participants underwent both [<jats:sup>18</jats:sup>F]AlF-NOTA-FAPI-04 and [<jats:sup>18</jats:sup>F]FDG within 14 days. Histopathologic examination, morphological imaging, and/or follow-up imaging were used as a reference for the final diagnosis. We recorded the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of [<jats:sup>18</jats:sup>F]AlF-NOTA-FAPI-04 and [<jats:sup>18</jats:sup>F]FDG PET/CT for detecting local recurrence, lymph node metastasis and distant metastasis. The SUVmax and background ratio (TBR) of local recurrence and metastases between [<jats:sup>18</jats:sup>F]FDG and [<jats:sup>18</jats:sup>F]AlF-NOTA-FAPI-04 PET/CT were compared using paired-sample t tests.ResultsForty-seven patients (27 males, aged 25–68 years) with gastric cancer after curative resection (27 with adenocarcinoma, 17 with signet ring cell carcinoma and 4 with mucinous adenocarcinoma) were included in the study. [<jats:sup>18</jats:sup>F]AlF-NOTA-FAPI-04 accumulation was significantly greater than that of [<jats:sup>18</jats:sup>F]FDG in terms of local recurrence (SUVmax, 11.65 vs 3.48, p&amp;lt; 0.0001; TBR, 12.93 vs 2.94, p&amp;lt; 0.0001), lymph node metastasis (SUVmax, 13.45 vs 3.05, p=0.003875; TBR, 12.43 vs 2.21, p=0.001661), and distant metastasis (SUVmax, 11.89 vs 2.96, p &amp;lt; 0.0001; TBR, 13.32 vs 2.32, p&amp;lt; 0.0001). Despite no statistical comparison was made with [<jats:sup>18</jats:sup>F]FDG, [<jats:sup>18</jats:sup>F]AlF-NOTA-FAPI-04 imaging exhibited high levels of sensitivity, specificity, PPV, NPV, and accuracy for detecting postoperative local recurrence, lymph node metastasis, and distant metastasis in patients with gastric cancer.Conclusion[<jats:sup>18</jats:sup>F]AlF-NOTA-FAPI-04 has demonstrated potential for more accurate tumor re-evaluation in GC, thus enhancing treatment decision-making.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneous SSTR2 target expression and a novel KIAA1549::BRAF fusion clone in a progressive metastatic lesion following 177Lutetium-DOTATATE molecular radiotherapy in neuroblastoma: a case report","authors":"Se Whee Sammy Park, Susanne Fransson, Fredrik Sundquist, Joachim N. Nilsson, Per Grybäck, Sandra Wessman, Jacob Strömgren, Anna Djos, Henrik Fagman, Helene Sjögren, Kleopatra Georgantzi, Nikolas Herold, Per Kogner, Dan Granberg, Mark N. Gaze, Tommy Martinsson, Kasper Karlsson, Jakob J. E. Stenman","doi":"10.3389/fonc.2024.1408729","DOIUrl":"https://doi.org/10.3389/fonc.2024.1408729","url":null,"abstract":"In this case report, we present the treatment outcomes of the first patient enrolled in the LuDO-N trial. The patient is a 21-month-old girl diagnosed with high-risk neuroblastoma (NB) and widespread skeletal metastasis. The patient initially underwent first-line therapy according to SIOPEN HRNBL-1 but was switched to second-line treatments due to disease progression, and she was finally screened for enrollment in the LuDO-N trial due to refractory disease. Upon enrollment, the patient received two rounds of the radiolabeled somatostatin analogue lutetium-177 octreotate (<jats:sup>177</jats:sup>Lu-DOTATATE), which was well tolerated. A dosimetry analysis revealed a heterogeneous uptake across tumor lesions, resulting in a significant absorbed dose of 54 Gy in the primary tumor, but only 2 Gy at one of the metastatic sites in the distal femur. While the initial treatment response showed disease stabilization, the distal femoral metastasis continued to progress, leading to the eventual death of the patient. A tissue analysis of the biopsies collected throughout the course of the disease revealed heterogeneous drug target expression of somatostatin receptor 2 (SSTR2) across and within tumor lesions. Furthermore, genomic profiling revealed a novel <jats:italic>KIAA1549</jats:italic>::<jats:italic>BRAF</jats:italic> fusion oncogene amplification in the distal femoral metastasis at recurrence that might be related with resistance to radiation, possibly through the downregulation of SSTR2. This case report demonstrates a mixed response to molecular radiotherapy (MRT) with <jats:sup>177</jats:sup>Lu-DOTATATE. The observed variation in SSTR2 expression between tumor lesions suggests that heterogeneous target expression may have been the reason for treatment failure in this patient’s case. Further investigation within the LuDO-N trial will give a more comprehensive understanding of the correlation between SSTR2 expression levels and treatment outcomes, which will be important to advance treatment strategies based on MRT for children with high-risk NB.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-conization pathological upgrading and outcomes of 466 patients with low-grade cervical intraepithelial neoplasia","authors":"Yulin Guo, Hongning Cai, Qiuzi Peng, Ying Wang, Lu Li, Miao Zou, Jinyue Guo, Chaonan Wang, Xufeng Wu, Quanfu Ma","doi":"10.3389/fonc.2024.1449080","DOIUrl":"https://doi.org/10.3389/fonc.2024.1449080","url":null,"abstract":"IntroductionThe management of patients with low-grade cervical intraepithelial neoplasia (CIN1) remains controversial. We analyzed the pathological upgrading rates of patients with CIN1 undergoing conization, identifying influencing factors, and compared their outcomes to those of patients with CIN1 receiving follow-up only.MethodsThis retrospective study included 466 patients with CIN1 confirmed by histopathology and treated with conization. Postoperative pathological upgrading was determined and its influencing factors were identified. We also analyzed post-conization outcomes, examining the rate of persistent/recurrent CIN1 and its influencing factors, and comparing these results to those of patients receiving follow-up only.ResultsThe pathological upgrading rate of patients with CIN1 after conization was 21.03% (98/466), and the influencing factors were preoperative high-risk human papillomavirus (HR-HPV) infection and cytological results. The upgrading rates of HR-HPV positive and negative patients were 22.05% and 0.00%, respectively (<jats:italic>χ</jats:italic><jats:sup>2</jats:sup> = 5.03, <jats:italic>P</jats:italic>=0.03). The upgrading rate of patients with cytological results negative for intraepithelial lesion malignancy was 10.94%, while the upgrading rates of atypical squamous cells, cannot exclude high-grade lesion(ASC-H) and high-grade squamous intraepithelial lesion(HSIL) groups were 47.37% and 52.94%, respectively (<jats:italic>χ</jats:italic><jats:sup>2 =</jats:sup> 22.7, <jats:italic>P</jats:italic>=0.03). Persistent/recurrent CIN1 rates in the conization group were 21.24%, 15.97%, and 6.67% at 6, 12, and 24 months, respectively, significantly lower than those in the follow-up only group. The CIN2 progression rate in the conization group (0.26%) during the 24-month follow-up period was also significantly lower than that in the follow-up only group (15.15%; <jats:italic>χ</jats:italic><jats:sup>2 =</jats:sup> 51.68, <jats:italic>P</jats:italic>&amp;lt;0.01). The only factor influencing postoperative persistent/recurrent CIN1 was preoperative HR-HPV status. No patients who were HR-HPV negative preoperatively exhibited persistent/recurrent CIN1, compared with 25.55% of those who were HR-HPV positive preoperatively (<jats:italic>χ</jats:italic><jats:sup>2</jats:sup> = 4.40, <jats:italic>P</jats:italic>=0.04).DiscussionThe risk of progression to CIN2+ in the medium term is higher in patients with CIN1 receiving follow-up than in those undergoing conization. Doctors should refer to the guidelines but comprehensively consider age, fertility requirements, preoperative HR-HPV and cytological results, follow-up conditions, and other factors to select the most appropriate treatment strategy for patients with CIN1.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The value of multiparameter MRI of early cervical cancer combined with SCC-Ag in predicting its pelvic lymph node metastasis","authors":"Xiaoqian Xu, Fenghai Liu, Xinru Zhao, Chao Wang, Da Li, Liqing Kang, Shikai Liu, Xiaoling Zhang","doi":"10.3389/fonc.2024.1417933","DOIUrl":"https://doi.org/10.3389/fonc.2024.1417933","url":null,"abstract":"PurposeTo investigate the value of multiparameter MRI of early cervical cancer (ECC) combined with pre-treatment serum squamous cell carcinoma antigen (SCC-Ag) in predicting its pelvic lymph node metastasis (PLNM).Material and methods115 patients with pathologically confirmed FIGO IB1~IIA2 cervical cancer were retrospectively included and divided into the PLNM group and the non-PLNM group according to pathological results. Quantitative parameters of the primary tumor include K<jats:sup>trans</jats:sup>, K<jats:sub>ep</jats:sub>, V<jats:sub>e</jats:sub> from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), ADC<jats:sub>mean</jats:sub>, ADC<jats:sub>min</jats:sub>, ADC<jats:sub>max</jats:sub>, D, D<jats:sup>*</jats:sup> and f from intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) were measured. Pre-treatment serum SCC-Ag was obtained. The difference of the above parameters between the two groups were compared using the student t-test or Mann-Whitney U test. Multivariate Logistic regression analysis was performed to determine independent risk factors. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic efficacy of individual parameters and their combination in predicting PLNM from ECC.ResultsThe PLNM group presented higher SCC-Ag [14.25 (6.74,36.75) ng/ml vs.2.13 (1.32,6.00) ng/ml, <jats:italic>P</jats:italic>&amp;lt;0.001] and lower K<jats:sup>trans</jats:sup> (0.51 ± 0.20 min<jats:sup>-1</jats:sup> vs.0.80 ± 0.33 min<jats:sup>-1</jats:sup>, <jats:italic>P</jats:italic> &amp;lt; 0.001), ADC<jats:sub>mean</jats:sub> (0.85 ± 0.09 mm/s<jats:sup>2</jats:sup> vs.1.06 ± 0.35 mm/s<jats:sup>2</jats:sup>, <jats:italic>P</jats:italic>&amp;lt;0.001), ADC<jats:sub>min</jats:sub> [0.67 (0.61,0.75) mm/s<jats:sup>2</jats:sup> vs. 0.75 (0.64,0.90) mm/s<jats:sup>2</jats:sup>, <jats:italic>P</jats:italic> = 0.012] and f (0.91 ± 0.09 vs. 0.27 ± 0.14, <jats:italic>P</jats:italic> = 0.001) than the non-LNM group. Multivariate analysis showed that SCC-Ag (OR = 1.154, <jats:italic>P</jats:italic> = 0.007), K<jats:sup>trans</jats:sup> (OR=0.003, <jats:italic>P</jats:italic> &amp;lt; 0.001) and f (OR = 0.001, <jats:italic>P</jats:italic>=0.036) were independent risk factors of PLNM. The combination of SCC-Ag, K<jats:sup>trans</jats:sup> and f possessed the best predicting efficacy for PLNM with an area under curve (AUC) of 0.896, which is higher than any individual parameter: SCC-Ag (0.824), K<jats:sup>trans</jats:sup> (0.797), and f (0.703). The sensitivity and specificity of the combination were 79.1% and 94.0%, respectively.ConclusionsQuantitative parameters K<jats:sup>trans</jats:sup> and f derived from DCE-MRI and IVIM-DWI of primary tumor and SCC-Ag have great value in predicting PLNM. The diagnostic efficacy of their combination has been further improved.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo characterization of brain tumor biomechanics: magnetic resonance elastography in intracranial B16 melanoma and GL261 glioma mouse models","authors":"Anastasia Janas, Jakob Jordan, Gergely Bertalan, Tom Meyer, Jan Bukatz, Ingolf Sack, Carolin Senger, Melina Nieminen-Kelhä, Susan Brandenburg, Irina Kremenskaia, Kiril Krantchev, Sanaria Al-Rubaiey, Susanne Mueller, Stefan Paul Koch, Philipp Boehm-Sturm, Rolf Reiter, Daniel Zips, Peter Vajkoczy, Gueliz Acker","doi":"10.3389/fonc.2024.1402578","DOIUrl":"https://doi.org/10.3389/fonc.2024.1402578","url":null,"abstract":"IntroductionMagnetic Resonance Elastography (MRE) allows the non-invasive quantification of tumor biomechanical properties <jats:italic>in vivo</jats:italic>. With increasing incidence of brain metastases, there is a notable absence of appropriate preclinical models to investigate their biomechanical characteristics. Therefore, the purpose of this work was to assess the biomechanical characteristics of B16 melanoma brain metastases (MBM) and compare it to murine GL261 glioblastoma (GBM) model using multifrequency MRE with tomoelastography post processing.MethodsIntracranial B16 MBM (n = 6) and GL261 GBM (n = 7) mouse models were used. Magnetic Resonance Imaging (MRI) was performed at set intervals after tumor implantation: 5, 7, 12, 14 days for MBM and 13 and 22 days for GBM. The investigations were performed using a 7T preclinical MRI with 20 mm head coil. The protocol consisted of single-shot spin echo-planar multifrequency MRE with tomoelastography post processing, contrast-enhanced T1- and T2-weighted imaging and diffusion-weighted imaging (DWI) with quantification of apparent diffusion coefficient of water (ADC). Elastography quantified shear wave speed (SWS), magnitude of complex MR signal (T2/T2*) and loss angle (φ). Immunohistological investigations were performed to assess vascularization, blood-brain-barrier integrity and extent of glucosaminoglucan coverage.ResultsVolumetric analyses displayed rapid growth of both tumor entities and softer tissue properties than healthy brain (healthy: 5.17 ± 0.48, MBM: 3.83 ± 0.55, GBM: 3.7 ± 0.23, [m/s]). SWS of MBM remained unchanged throughout tumor progression with decreased T2/T2* intensity and increased ADC on days 12 and 14 (p&amp;lt;0.0001 for both). Conversely, GBM presented reduced φ values on day 22 (p=0.0237), with no significant alterations in ADC. Histological analysis revealed substantial vascularization and elevated glycosaminoglycan content in both tumor types compared to healthy contralateral brain.DiscussionOur results indicate that while both, MBM and GBM, exhibited softer properties compared to healthy brain, imaging and histological analysis revealed different underlying microstructural causes: hemorrhages in MBM and increased vascularization and glycosaminoglycan content in GBM, further corroborated by DWI and T2/T2* contrast. These findings underscore the complementary nature of MRE and its potential to enhance our understanding of tumor characteristics when used alongside established techniques. This comprehensive approach could lead to improved clinical outcomes and a deeper understanding of brain tumor pathophysiology.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiation of pheochromocytoma and adrenal lipoid adenoma by radiomics: are enhanced CT scanning images necessary?","authors":"Shi he Liu, Pei Nie, Shun li Liu, Dapeng Hao, Juntao Zhang, Rui Sun, Zhi tao Yang, Chuan yu Zhang, Qing Fu","doi":"10.3389/fonc.2024.1339671","DOIUrl":"https://doi.org/10.3389/fonc.2024.1339671","url":null,"abstract":"PurposeTo establish various radiomics models based on conventional CT scan images and enhanced CT images, explore their value in the classification of pheochromocytoma (PHEO) and lipid-poor adrenal adenoma (LPA) and screen the most parsimonious and efficient modelMethodsThe clinical and imaging data of 332 patients (352 lesions) with PHEO or LPA confirmed by surgical pathology in the Affiliated Hospital of Qingdao University were retrospectively analyzed. The region of interest (ROI) on conventional and enhanced CT images was delineated using ITK-SNAP software. Different radiomics signatures were constructed from the radiomics features extracted from conventional and enhanced CT images, and a radiomics score (Rad score) was calculated. A clinical model was established using demographic features and CT findings, while radiomics nomograms were established using multiple logistic regression analysis.The predictive efficiency of different models was evaluated using the area under curve (AUC) and receiver operating characteristic (ROC) curve. The Delong test was used to evaluate whether there were statistical differences in predictive efficiency between different models.ResultsThe radiomics signature based on conventional CT images showed AUCs of 0.97 (training cohort, 95% CI: 0.95∼1.00) and 0.97 (validation cohort, 95% CI: 0.92∼1.00). The AUCs of the nomogram model based on conventional scan CT images and enhanced CT images in the training cohort and the validation cohort were 0.97 (95% CI: 0.95∼1.00) and 0.97 (95% CI: 0.94~1.00) and 0.98 (95% CI: 0.97∼1.00) and 0.97 (95% CI: 0.94∼1.00), respectively. The prediction efficiency of models based on enhanced CT images was slightly higher than that of models based on conventional CT images, but these differences were statistically insignificant(P&amp;gt;0.05).ConclusionsCT-based radiomics signatures and radiomics nomograms can be used to predict and identify PHEO and LPA. The model established based on conventional CT images has great identification and prediction efficiency, and it can also enable patients to avoid harm from radiation and contrast agents caused by the need for further enhancement scanning in traditional image examinations.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142224657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identify BCAT1 plays an oncogenic role and promotes EMT in KIRC via single cell RNA-seq and experiment","authors":"Shiqing Li, Yinsheng Guo, Guanhua Zhu, Lu Sun, Feng Zhou","doi":"10.3389/fonc.2024.1446324","DOIUrl":"https://doi.org/10.3389/fonc.2024.1446324","url":null,"abstract":"BackgroundKidney renal clear cell carcinoma (KIRC) is a major subtype of renal cell carcinoma with poor prognosis due to its invasive and metastatic nature. Despite advances in understanding the molecular underpinnings of various cancers, the role of branched-chain amino acid transferase 1 (BCAT1) in KIRC remains underexplored. This study aims to fill this gap by investigating the oncogenic role of BCAT1 in KIRC using single-cell RNA-seq data and experimental validation.MethodsSingle-cell transcriptomic data GSE159115 was utilized to investigate potential biomarkers in KIRC. After screening, we used BCAT1 as a target gene and investigated its function and mechanism in KIRC through databases such as TCGA-GTEx, using genome enrichment analysis (GSEA), genome variation analysis (GSVA), gene ontology (GO) and Kyoto Encyclopedia of the Genome (KEGG). BCAT1 expression was detected in clinical tissue samples using Western Blotting (WB) and immunohistochemical (IHC) staining techniques. We established cell lines stably overexpressing and knocking down BCAT1 and performed WB, qRT-PCR, cell scratch assay and transwell assay.ResultsBCAT1 was highly expressed in KIRC and was associated with disease prognosis and TME. Patients with mutations in the BCAT1 gene had shorter overall survival (OS) and disease-free survival (DFS). patients with high BCAT1 expression had shorter OS, progression-free interval (PFI), and disease-specific survival (DSS). GSEA showed that BCAT1 was significantly enriched in epithelial mesenchymal transition (EMT). Bioinformatics analysis and WB and IHC staining showed that BCAT1 expression was higher in KIRC than in paracancerous tissues. <jats:italic>In vitro</jats:italic> experiments confirmed that BCAT1 in KIRC cells may promote EMT affecting its invasion, migration. We constructed a protein interaction network (PPI) to hypothesize proteins that may interact with BCAT1. Single-sample gene set enrichment analysis (ssGSEA) revealed the immune infiltration environment of BCAT1. Furthermore, hypomethylation of the BCAT1 promoter region in KIRC may contribute to disease progression by promoting BCAT1 expression.ConclusionBCAT1 promotes KIRC invasion and metastasis through EMT and has prognostic predictive value and potential as a biomarker. It may become a novel biomarker.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer","authors":"Nicolas Fraunhoffer, Carlos Teyssedou, Patrick Pessaux, Martin Bigonnet, Nelson Dusetti, Juan Iovanna","doi":"10.3389/fonc.2024.1437200","DOIUrl":"https://doi.org/10.3389/fonc.2024.1437200","url":null,"abstract":"BackgroundThe utilization of modified FOLFIRINOX (mFFX) therapy has shown notable advancements in patient outcomes in both localized and metastatic PDAC. Nevertheless, the effectiveness of mFFX treatment comes at the cost of elevated toxicity, leading to its restriction to patients with adequate performance status. Consequently, the administration of mFFX is contingent upon patient performance rather than rational criteria. The ideal scenario would involve the ability to assess the sensitivity of each drug within the mFFX regimen, minimizing unnecessary toxicity without compromising clinical benefits.MethodsWe developed transcriptomic signatures for each drug of the mFFX regimen (5FU, oxaliplatin and irinotecan) by integrating transcriptomic data from PDC, PDO and PDX with their corresponding chemo-response profiles to capture the biological components responsible for the response to each drug. We further validated the signatures in a cohort of 167 patients with advanced and metastatic PDAC.ResultsAll three signatures captured high responder patients for OS and PFS in the mFFX arm exclusively. We then studied the response of patients to 0, 1, 2 and 3 drugs and we identified a positive correlation between the number of drugs predicted as sensitive and the OS and PFS, and the with objective response rate.ConclusionsWe developed three novel transcriptome-based signatures which define sensitivity for each mFFX components that can be used to rationalize the administration of the mFFX regimen in patients with metastatic pancreatic cancer and could help to avoid unnecessary toxic effects.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers","authors":"Eva Chrenková, Hana Študentová, Kateřina Holá, Zuzana Kahounová, Romana Hendrychová, Karel Souček, Jan Bouchal","doi":"10.3389/fonc.2024.1394292","DOIUrl":"https://doi.org/10.3389/fonc.2024.1394292","url":null,"abstract":"BackgroundProstate cancer is the second leading cause of male cancer-related deaths in Western countries, which is predominantly attributed to the metastatic castration-resistant stage of the disease (CRPC). There is an urgent need for better prognostic and predictive biomarkers, particularly for androgen receptor targeted agents and taxanes.MethodsWe have searched the PubMed database for original articles and meta-analyses providing information on blood-based markers for castration-resistant prostate cancer monitoring, risk group stratification and prediction of therapy response.ResultsThe molecular markers are discussed along with the standard clinical parameters, such as prostate specific antigen, lactate dehydrogenase or C-reactive protein. Androgen receptor (AR) alterations are commonly associated with progression to CRPC. These include amplification of AR and its enhancer, point mutations and splice variants. Among DNA methylations, a novel 5-hydroxymethylcytosine activation marker of TOP2A and EZH2 has been identified for the aggressive disease. miR-375 is currently the most promising candidate among non-coding RNAs and sphingolipid analysis has recently emerged as a novel approach.ConclusionsThe promising biomarkers have the potential to improve the care of metastatic prostate cancer patients, however, they need further validation for routine implementation.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoplasmic reticulum stress response pathway-mediated cell death in ovarian cancer","authors":"Qiaochu Chen, Chan Li, Wei Wei, Jia Li, Fangyuan Liu, Yuqian Fu, Liping Tang, Fengjuan Han","doi":"10.3389/fonc.2024.1446552","DOIUrl":"https://doi.org/10.3389/fonc.2024.1446552","url":null,"abstract":"The endoplasmic reticulum (ER) is one of the largest organelles, and Endoplasmic Reticulum Stress Response Pathway is a series of responses triggered by the homeostatic imbalance of the ER and the state in which unfolded or misfolded proteins accumulate in the ER, which can trigger cell death. Cell death plays a crucial role in the development of diseases such as gynecological oncology. Herein, we review the current research on the response and ovarian cancer, discussing the key sensors (IRE1, PERK, ATF6), and the conditions under which it occurs (Ca<jats:sup>2+</jats:sup> homeostasis disruption, hypoxia, others). Using the response as a starting point, provide a comprehensive overview of the relationship with the four types of cell death (apoptosis, autophagy, immunogenic cell death, paraptosis) in an attempt to provide new targeted therapeutic strategies for the organelle-Endoplasmic Reticulum Stress Response Pathway-cell death in ovarian cancer therapy.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}